Literature DB >> 22298457

Dehydrocorydaline inhibits breast cancer cells proliferation by inducing apoptosis in MCF-7 cells.

Zengtao Xu1, Xiuping Chen, Shu Fu, Jiaolin Bao, Yuanye Dang, Mingqing Huang, Lidian Chen, Yitao Wang.   

Abstract

Dehydrocorydaline is an alkaloid isolated from traditional Chinese herb Corydalis yanhusuo W.T. Wang. We discovered that it possessed anti-tumor potential during screening of anti-tumor natural products from Chinese medicine. In this study, its anti-tumor potential was investigated with breast cancer line cells MCF-7 in vitro. The anti-proliferative effect of dehydrocorydaline was determined by MTT assay and the mitochondrial membrane potential (Δ Ψ m) was monitored by JC-1 staining. DNA fragments were visualized by Hoechst 33342 staining and DNA ladder assay. Apoptotic related protein expressions were measured by Western blotting. Dehydrocorydaline significantly inhibited MCF-7 cell proliferation in a dose- dependent manner, which could be reversed by a caspase-8 inhibitor, Z-IETD-FMK. Dehydrocorydaline increased DNA fragments without affecting ΔΨm. Western blotting assay showed that dehydrocorydaline dose-dependently increased Bax protein expression and decreased Bcl-2 protein expression. Furthermore, dehydrocorydaline induced activation of caspase-7,-8 and the cleavage of PARP without affecting caspase-9. These results showed that dehydrocorydaline inhibits MCF-7 cell proliferation by inducing apoptosis mediated by regulating Bax/Bcl-2, activating caspases as well as cleaving PARP.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22298457     DOI: 10.1142/S0192415X12500140

Source DB:  PubMed          Journal:  Am J Chin Med        ISSN: 0192-415X            Impact factor:   4.667


  14 in total

1.  Isolation and chemopreventive evaluation of novel naphthoquinone compounds from Alkanna tinctoria.

Authors:  Nguyen Huu Tung; Guang-Jian Du; Chun-Su Yuan; Yukihiro Shoyama; Chong-Zhi Wang
Journal:  Anticancer Drugs       Date:  2013-11       Impact factor: 2.248

2.  System-level multi-target drug discovery from natural products with applications to cardiovascular diseases.

Authors:  Chunli Zheng; Jinan Wang; Jianling Liu; Mengjie Pei; Chao Huang; Yonghua Wang
Journal:  Mol Divers       Date:  2014-05-04       Impact factor: 2.943

3.  Antinociceptive effects of dehydrocorydaline in mouse models of inflammatory pain involve the opioid receptor and inflammatory cytokines.

Authors:  Zhi-Yu Yin; Lu Li; Shuai-Shuai Chu; Qing Sun; Zheng-Liang Ma; Xiao-Ping Gu
Journal:  Sci Rep       Date:  2016-06-07       Impact factor: 4.379

4.  Dehydrocorydaline attenuates bone cancer pain by shifting microglial M1/M2 polarization toward the M2 phenotype.

Authors:  Wenwen Huo; Ying Zhang; Yue Liu; Yishan Lei; Rao Sun; Wei Zhang; Yulin Huang; Yanting Mao; Chenchen Wang; Zhengliang Ma; Xiaoping Gu
Journal:  Mol Pain       Date:  2018 Jan-Dec       Impact factor: 3.395

5.  Cytotoxicity enhancement in MDA-MB-231 cells by the combination treatment of tetrahydropalmatine and berberine derived from Corydalis yanhusuo W. T. Wang.

Authors:  Yan Zhao; Jian-Li Gao; Jian-Wei Ji; Min Gao; Qiao-Shan Yin; Qiao-Li Qiu; Chuan Wang; Shu-Zhan Chen; Juan Xu; Ren-Shang Liang; Yan-Zi Cai; Xia-Fei Wang
Journal:  J Intercult Ethnopharmacol       Date:  2014-05-27

6.  Erythropoietin Exacerbates Inflammation and Increases the Mortality of Histoplasma capsulatum-Infected Mice.

Authors:  Gisele Aparecida Locachevic; Priscilla Aparecida Tartari Pereira; Adriana Secatto; Caroline Fontanari; Alyne Fávero Galvão; Morgana Kelly Borges Prado; Karina Furlani Zoccal; Tânia Petta; Luiz Alberto Beraldo Moraes; Simone Gusmão Ramos; Fabíola Attie de Castro; Carlos Artério Sorgi; Lúcia Helena Faccioli
Journal:  Mediators Inflamm       Date:  2015-10-11       Impact factor: 4.711

7.  Dehydrocorydaline promotes myogenic differentiation via p38 MAPK activation.

Authors:  Miran Yoo; Sang-Jin Lee; Yong Kee Kim; Dong-Wan Seo; Nam-In Baek; Jae-Ha Ryu; Jong-Sun Kang; Gyu-Un Bae
Journal:  Mol Med Rep       Date:  2016-08-19       Impact factor: 2.952

8.  A Novel Aurora-A Inhibitor (MLN8237) Synergistically Enhances the Antitumor Activity of Sorafenib in Hepatocellular Carcinoma.

Authors:  Kai Zhang; Ting Wang; Hao Zhou; Bing Feng; Ying Chen; Yingru Zhi; Rui Wang
Journal:  Mol Ther Nucleic Acids       Date:  2018-09-12       Impact factor: 8.886

9.  Identification of Metabolites of the Cardioprotective Alkaloid Dehydrocorydaline in Rat Plasma and Bile by Liquid Chromatography Coupled with Triple Quadrupole Linear Ion Trap Mass Spectrometry.

Authors:  Huanyu Guan; Kaitong Li; Xiaoming Wang; Xiaomei Luo; Meifeng Su; Wenting Tan; Xiaoyan Chang; Yue Shi
Journal:  Molecules       Date:  2017-10-10       Impact factor: 4.411

10.  Dehydrocorydaline inhibits the tumorigenesis of breast cancer MDA‑MB‑231 cells.

Authors:  Ying Huang; Hui Huang; Shiying Wang; Feixiang Chen; Gang Zheng
Journal:  Mol Med Rep       Date:  2020-05-05       Impact factor: 2.952

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.